Page 74 - Amgen News Today

This Vanguard growth fund is home to some of the world's most innovative companies.

Can a patentee really just take a pass on alleging that an accused product meets a limitation in an asserted claim, even where the case involves complex technology? Thats the upshot of the courts...

Can a patentee really just take a pass on alleging that an accused product meets a limitation in an asserted claim, even where the case involves complex technology?...

PDS Planning Inc raised its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,171 shares of the medical research company’s stock after acquiring an additional 57 shares during the quarter. […]

U.S. stocks are up firmly in positive territory Tuesday afternoon, extending early gains as several counters across various sectors continue to attract strong buying amid expectations of strong earnings from technology majors.

Beaumont Asset Management L.L.C. boosted its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,687 shares of the medical research company’s stock after buying an additional 62 shares during the quarter. Beaumont Asset […]

These two pharma stocks have followed distinct paths of late. Which is the better investment?

Masso Torrence Wealth Management Inc. acquired a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,446 shares of the medical research company’s stock, valued at approximately $416,000. Several other hedge funds and […]

U.S. stocks are up firmly in positive territory Tuesday afternoon, extending early gains as several counters across various sectors continue to attract strong buying amid expectations of strong earnings from technology majors.

Capital Investment Advisory Services LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,888 shares of the medical research company’s stock after selling 146 shares during the period. Capital Investment Advisory Services LLC’s holdings […]